Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer-Reference-Cited by-同舟云学术

Clinical implications of PNA‑sequencing as a complementary test for EGFR mutation analysis in human lung cancer

Published:2023-11-02 Issue:6 Volume:26 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Chen Yi-Lin¹,Lin Chien-Chung²,Yu Yu-Ting³,Chen Wan-Li¹,Yang Shu-Ching¹,Huang Wenya¹,Su Wu-Chou²,Chow Nan-Haw³,Ho Chung-Liang³

Affiliation:

1. Molecular Diagnostics Laboratory, Department of Pathology, National Cheng Kung University Hospital, Tainan 704, Taiwan, R.O.C.

2. Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan, R.O.C.

3. Department of Pathology, National Cheng Kung University Hospital, Tainan 704, Taiwan, R.O.C.

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference24 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

2. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC);Hsu;Int J Mol Sci,2019

3. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review);He;Int J Oncol,2021

4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC);Gelatti;Lung Cancer,2019

5. Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: A review;Guo;Front Oncol,2020